Slate Medicines Doses First Participant in Phase 1 Trial of Migraine Candidate SLTE-1009

Slate Medicines has dosed the first participant in a Phase 1 clinical trial evaluating SLTE-1009, its experimental monoclonal antibody for... Read More

The post Slate Medicines Doses First Participant in Phase 1 Trial of Migraine Candidate SLTE-1009 appeared first on citybiz.